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Abstract
The Brazilian network for genotyping is composed of 21 laboratories that perform and analyze genotyping tests for
all HIV-infected patients within the public system, performing approximately 25,000 tests per year. We assessed the
interlaboratory and intralaboratory reproducibility of genotyping systems by creating and implementing a local
external quality control evaluation. Plasma samples from HIV-1-infected individuals (with low and intermediate viral
loads) or RNA viral constructs with specific mutations were used. This evaluation included analyses of sensitivity
and specificity of the tests based on qualitative and quantitative criteria, which scored laboratory performance on a
100-point system. Five evaluations were performed from 2003 to 2008, with 64% of laboratories scoring over
80 points in 2003, 81% doing so in 2005, 56% in 2006, 91% in 2007, and 90% in 2008 (Kruskal-Wallis, p = 0.003).
Increased performance was aided by retraining laboratories that had specific deficiencies. The results emphasize
the importance of investing in laboratory training and interpretation of DNA sequencing results, especially in
developing countries where public (or scarce) resources are used to manage the AIDS epidemic.
Background
Since 1991, the Brazilian Government has implemented a
successful policy to guarantee universal free antiretroviral
therapy (ART) access to all HIV-1-infected individuals
according to local guidelines. There is also a laboratory
network supported by the Brazilian Ministry of Health for
HIV-1 monitoring, with 90 laboratories performing CD4
and CD8+ T cell counting and 83 laboratories performing
HIV-1 viral load testing for all infected individuals in the
country free of charge. There is also an established net-
work for HIV-1 genotyping, which was implemented in
2001. This network, the Brazilian Network for HIV-1
Genotyping (RENAGENO), is now composed of 21
laboratories that perform and analyze genotyping tests.
One laboratory was designated as a reference laboratory
(Retrovirology Laboratory of Federal University of Sao
Paulo, Brazil) that, in addition to performing genotype ana-
lyses, also performs troubleshooting, prepares quality con-
trol panels and evaluations, and performs custom analyses
of samples that fail to generate a result using licensed kits.
The choice of kits used by RENAGENO is made on an
annual basis and is related to the price of licensed kits at
the time of the decision. From 2001 to 2007, the platform
used was ViroSeq® v.2.6 (Applied Biosystems, CA, USA),
and since 2008, the platform has been the TRUGENE®
HIV-1 Genotyping Assay (Siemens Healthcare Diagnostics,
IL, USA). Interpretation of HIV resistance is based on a
local algorithm prepared by a group of Brazilian and inter-
national experts (available at http://algoritmo.aids.gov.br/
atualizacao_algoritmo/site/ and http://www.ablsa.com).
RENAGENO consists of around 300 infectious disease
physicians (Reference Physicians on Genotyping Interpre-
tation or RPGs) who are trained to act as clinical virolo-
gists and to provide expert advice on the interpretation of
HIV resistance tests and antiretroviral salvage therapy.
The work flow of RENAGENO is as follows: (i) the attend-
ing physician orders a genotyping test and completes a
form containing clinical data, including current and past
antiretroviral exposure and lab results, from the patients;
(ii) the request goes to the local RPG, who determines if
the request fulfills the Brazilian guidelines for the use of a
genotyping test; (iii) if authorized by the RPG, a sample is
collected and sent to a local RENAGENO lab; and (iv) the
result is sent to the RPG, who provides a written recom-
mendation for salvage therapy to the attending physician
according to the his/her interpretation of the case.
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RPGs convene once a year for four days to be retrained
as a part of a continuous education programme led by
experts in the field appointed by individuals from the
STD/AIDS and Viral Hepatitis Diseases Department of
the Brazilian Ministry of Health. New RPGs are trained in
a separate four-day meeting before entering the pro-
gramme. RPGs are volunteers who are an important part
of RENAGENO in terms of authorizing the request and
the use of resistance tests vis-a-vis the impact of expert
advice on the performance of salvage therapy (HAVANA)
[1] and the influence that HIV-1 resistance tests have in
the decision-making process of the physician [2].
RENAGENO had performed 54,594 tests as of Decem-
ber 2009 and is now set to perform 25,500 genotyping
tests/year. We have implemented a quality control and
assurance system to monitor the performance of the 21
laboratories that comprise the RENAGENO network. We
report here on the methodology used, as well as the per-
formance of the laboratories, in the first five external
quality control evaluations (EQAs) performed in 2003,
2005, 2006, 2007 and 2008.
Methods
Five external evaluations of the quality panels (EQA 1-5)
were employed from 2003 to 2008. In each year, between
10 and 21 laboratories were evaluated (14 laboratories
were evaluated in 2003, 15 in 2005, 16 in 2006, 21 in 2007,
and 10 in 2008). The overall criteria for evaluating the par-
ticipating laboratories are provided in Table 1. Briefly, it
was considered important to evaluate: (i) the ability of pur-
ifying RNA and PCR amplify the samples; (ii) the absence
of PCR carry over; (iii) the ability to obtain sequences of
all involved fragments; (iv) the ability to obtain good qual-
ity sequences; (v) and the ability to identify resistance-
related mutations in involved codons.
The weights provided for each category were arbitrarily
chosen according to the level of importance the members
of the panel that prepared the interpretation gave to each
step of the test. One sample with low viral load and one
sample with intermediate viral load was included in each
evaluating panel. The same weights was given to both
low and intermediate viral load samples since it was con-
sidered to be equally important for well-trained labora-
tories to obtain good quality results in any type of
samples. Correct interpretation of resistance vis-a-vis
available antiretrovirals were not evaluated since inter-
pretations may change over time and there are many
available algorithms for resistance interpretation.
Samples used
EQA 1, 3, 4 and 5 used panels made from clinical sam-
ples presenting specific drug resistance mutations and
polymorphisms in the reverse transcriptase and protease
regions of pol. For EQA_2, infectious clones with specific
antiretroviral mutations were constructed. Samples were
diluted with seronegative plasma and adjusted to have
viral loads of approximately 2000 (sample 1) and 10,000
(sample 2) copies of HIV-1 RNA/mL of plasma. Sample 1
and sample 2 came from different donors and had differ-
ent mutation profiles, and mutation profiles differed
among different EQA panels. All samples were from
clade B HIV strains. No samples without HIV have been
used. Informed consent was obtained from patients that
provided the samples. The determination of the “true
profile” of the clinical samples was performed by at least
two bidirectional independent sequencing reactions.
Performance evaluation
Qualitative criteria
Sensitivity
The objective was to evaluate the ability of a laboratory to
amplify and sequence two panels of samples; one panel
has samples that contain 2000 copies HIV RNA/mL and
Table 1 Criteria for laboratory evaluation
Sample 1 Sample 2
Qualitative variables
Positive PCR amplification
15 15 30
Genetic diversity of sequenced samples
Less than 2.2% 10 10 20
Quantitative variables
Number of obtained sequences
4 2 2
5 4 4
6 8 8
7 10 10 20
Correct interpretation of mutations
(codons)
Protease 1 1 1
2 1 1
3 1 1
4 1 1
5 1 1 10
Reverse transcriptase 1 1 1
2 1 1
3 1 1
4 1 1
5 1 1 10
Quality of sequences (Phred quality scores)
100% above 30 5 5
80-99% above 30 2.5 2.5 10
Total 100
(The viral load of sample 1 is 2000 copies/mL and the viral load of sample 2 is
10,000 copies/mL).
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the other panel has samples that contain 10,000 copies
RNA/mL. The smaller viral load is representative of the
lower detection limit of the commercial kits used.
Specificity
The objective was to evaluate the ability to amplify and gen-
erate sequences similar to the known profile of a specific
strain. Variation was accepted between sequences if it was
within the expected genetic diversity of the quasispecies of
the specific viruses or the expected misincorporation rate
of the PCR polymerase (~1/500 misincorporations) [3]. All
generated sequences from different evaluated laboratories
were aligned using ClustalX software, and a distance matrix
was generated using DNADIST software. We considered
the maximum genetic diversity of the analyzed region to be
2%, and therefore, for a 1.3-kb fragment, a maximum differ-
ence of 29 nucleotides would be expected (26 mutations
based on normal HIV-1 genetic diversity and three muta-
tions based on the polymerase misincorporation rate).
Thus, if the generated sequenced presented a distance that
was 0.022 greater than the consensus sequence (2.2% dis-
tance), the possibility of PCR carryover was considered.
Quantitative criteria
Number of generated sequences
The result was usually obtained by generating five to seven
sequences that cover the pol region of interest with the
necessary redundancy, including some sequences from the
5’ to 3’ direction and vice versa, based on the assumption
that a small number of generated sequences (less than five)
correlates with a greater possibility of misinterpretations.
Quality of generated sequences
The quality of generated chromatograms was interpreted
according to the fluorescence generated by each terminal
nucleotide. This fluorescence value was measured by the
Phred quality score (The Phred-Phrap Package software).
The chromatograms of good quality were those with
intensity signals over 30, which corresponds to 99.9%
accuracy of the base call (1/1000 probability that the base
is called incorrectly). For this analysis, the percentage of
nucleotides of each of the seven fragments with an emis-
sion signal over 30 was considered. Each laboratory was
awarded 5 points if 100% of nucleotides scored above 30,
2.5 points if 80-99.9% of nucleotides scored above 30, and
zero points for percentages below 80%.
Analysis of mutations in the reverse transcriptase and
protease regions
In this analysis, each participating laboratory was evalu-
ated on its ability to identify amino acid mutations at five
key positions in each genomic region from sequences
generated at the reference laboratory (Table 1).
Statistical analysis
To evaluate the general performance of labs over time, the
Kruskal-Wallis test was used for analysis of mean values.
Results
Table 2 describes the percentage of laboratories that
achieved the correct outcome on each of the criterion as a
percentage of the maximum score. The scores of genetic
diversity and all quantitative variables refer only to sam-
ples that did not fail to amplify (Table 2). Laboratories not
able to amplify any of the two samples received the score
of zero (Table 3). A positive PCR result was obtained
92.9% of the time when higher viral load samples were
analyzed and 90.5% (Table 2) of the time when lower viral
loads were used, and this performance was stable over
time (data not shown). According to the expected genetic
diversities of the viruses, PCR carryover has not been
detected in any sequenced samples. Drug resistant muta-
tions present in each panel containing viruses and
sequences sent for analysis is depicted in Table 4.
The overall performance scores of laboratories in the
EQA are depicted in Table 3. The data indicate that the
Table 2 Overall performance of laboratories according to
each evaluated criterion as a percentage of the
maximum score
Sample 1 Sample 2
Qualitative variables
Positive PCR amplification
90.5% 92.9% 91.7%
Genetic diversity of sequenced samples
Less than 2.2% 100% 100% 100%
Quantitative variables
Number of obtained sequences
4 0% 0%
5 6.0% 4.8%
6 6.0% 3.6%
7 75.9% 80.7% 88.6%
Correct interpretation of mutations
(codons)
Protease 1 0% 0%
2 1.2% 1.2%
3 0% 0%
4 1.2% 1.2%
5 85.7% 88.1% 89.3%
Reverse transcriptase 1 0% 0%
2 1.2% 1.2%
3 0% 0%
4 1.2% 1.2%
5 85.7% 88.1% 89.3%
Quality of sequences (Phred quality
scores)
100% above 30 22.7% 25.0% 23.8%
The results correspond to the mean values of the five evaluations. The viral
load of sample 1 is 2000 copies/mL and the viral load of sample 2 is 10,000
copies/mL.
Souza et al. Journal of the International AIDS Society 2011, 14:45
http://www.jiasociety.org/content/14/1/45
Page 3 of 6
overall scores improved over time. As shown in the
table, 64.3% of laboratories scored over 80 points in
2003, 81.7% did so in 2005, 81.1% in 2006, 90.5% in
2007, and 89.5% in 2008 (Kruskal-Wallis statistic on
medians among groups over time = 16.16, p = 0.003).
No clear reason has been detected to justify some
laboratories’ score fluctuation between panels as seen
for laboratories 3, 6, 11 and 16.
Retraining has been performed in laboratories 5, 6 and
9 after the first evaluation, in laboratory 16 after the third
evaluation and in laboratory 20 after the fourth evalua-
tion according to the specific needs of each laboratory
detected in the EQA evaluation (data on file). Retraining
included principles of preventing PCR carryover, specific
laboratory technical procedures and sequence editing
processes. A small group of technicians from the refer-
ence laboratory and technicians from the company that
produced the licensed genotype kits were responsible for
conducting the retraining.
Discussion
We describe here a methodology that was created to eval-
uate Brazilian laboratories that assist the Brazilian Ministry
of Health in its genotyping network. All participating
laboratories are public laboratories, most of which are
located at public universities and have primary activities
related to research as opposed to clinical care assistance.
Using this novel method to evaluate laboratories, we intro-
duced some variables to refine the evaluation of the
laboratories and laboratory personnel with respect to the
ability of each laboratory to generate results and to evalu-
ate the sensitivity of each laboratory system using low viral
load samples as described in the Methods section.
With this method, we were also able to evaluate the
quality of the generated sequences by measuring the inten-
sity of the signal, and we were able to evaluate the possibi-
lity of generating incorrect results by analyzing the genetic
diversity of generated sequences. It has been pointed out
that one of the weak points in homogeneity between labs
may be the proficiency in the sequence editing process
among different individuals [4]. Furthermore, we encour-
aged lab personnel to interpret the sequences and evalu-
ated personnel in their ability to recognize expected
mutations, including insertions and deletions, among
sequences generated elsewhere (data on file).
Table 3 Overall performance evaluation in number of
points (out of a maximum of 100 points) and standard-
deviation (SD) for each evaluation
LAB EQA1 EQA 2 EQA 3 EQA 4 EQA 5
1 30 0 NA NA NA
2 96 80 80 88.2 90
3 100 96.5 75 96.8 86.1
4 96 99.2 95 98.2 88.7
5 50 84.3 95 98.2 84.8
6 0 47.1 49 83.2 23.4
7 90 99.6 97.5 97.9 88.4
8 90 100 NA NA NA
9 30 NA 88 97.5 88.7
10 0 98.2 95 97.5 86.7
11 100 100 100 75.9 90
12 95 95 95 98.2 88.7
13 95 NA 85 98.2 88.7
14 NA 92.3 95 98.2 NA
15 100 95 95 97.9 NA
16 NA 100 45 98.2 90
17 NA NA 93 98.2 86.1
18 NA NA NA 97.9 85.4
19 NA NA 80 97.9 89.7
20 NA NA NA 10.5 88.7
21 NA NA NA 98.2 88.7
22 NA NA NA 97.9 90
23 NA NA NA 97.5 74.4
Mean (SD) 69.4 (± 38.73) 84.8 (± 36.60) 85.1(± 16.77) 91.5 (± 19.47) 84.1 (± 15.11).
% > 80 64.3 85.7 81.1 90.5 89.5.
LAB = the code number for each evaluated laboratory. EQA = External Quality
Control Evaluation. EQA1 was performed in 2003, EQA2 in 2005, EQA3 in
2006, EQA4, in 2007, and EQA5 in 2008. NA = not available due to the
absence of participation of a specific laboratory in the network or in the
evaluation. % > 80 refers to the percentage of participating labs that scored
more than 80 points. Laboratories that were not able to PCR amplify both
samples received a score equal zero.
Table 4 Drug resistance mutations present in each EQA panel
VL1 VL2
PROTEASE REVERSE TRANSCRIPTASE PROTEASE REVERSE TRANSCRIPTASE
EQA1 WT WT L10V, M36M/I WT
EQA2 V77I M184V, T215Y, K103N, A98G, P225H I54V, L63P, A71V, V82A, L90M WT
EQA3 L10F, K20R, L33F, I54L, V82A Y181C, R211K, T215C L10V, L63P, V77I M41L, M184V, Y188L, L210W, T215Y
EQA4 L10F, L63P, V77I, I84V, I93L D67N, K70R, M184V, T215T/I, K219E K20T, M46I, L63P, A71T, N88G M41L, K103N, V118I, M184V, T215Y
EQA5 E35D, I62V, V71T, I84I, L90L/M K103N, M184M, R221K, L214F, T215L E35D, I62V, A71T, I84I, L90L/M K103N, M184M, R211K, L214F, T215L
(VL1 = viral load 1 of 2000 copies/mL and VL2 = 10,000 copies/mL. WT = wild type virus. A total of five codons at the protease and five codons at reverse
transcriptase were selected for analysis. In the absence of drug resistance mutations, randomly selected wild type codons were chosen for the correct
interpretation of mutations analysis. In case of ambiguities - mixed viruses population, i.e, M36M/I - we scored as correct only labs that reported the presence of
both amino acids.)
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This external quality control evaluation also enables us
to detect, in an active manner, laboratories that need
retraining in a more dedicated fashion or to exclude spe-
cific under-performing labs from the network. Specialists
from the diagnostic companies that sold the kits per-
formed retraining, upon request from the Ministry of
Health HIV/AIDS Department, when scores were found
to be low. As noted in Table 3, low performance was not
common, and in general, labs showed improvement after
specific retraining.
One interesting study evaluating the proficiency of the
sequencing editing process between different laboratories
produced panels of HIV-1 isolates from subtypes B, C
and F [4]. These strains presented specific drug resistance
mutations and viral loads between 5000 and 10,000
copies/mL [4]. We chose to use clinical samples rather
than viral clones for four of the five evaluations in this
study in the interest of maintaining a realistic scenario
and increasing the complexity of laboratory manipulation
and interpretation as suggested by others [5,6]. Nonethe-
less, our second evaluation used RNA viral constructions
and the performances of the laboratories were, in general,
similar to those observed in subsequent evaluations
(EQA 3, 4 and 5). The results show that, overall, the aver-
age performance of the laboratories was adequate, with
82.4% of evaluations resulting in scores exceeding 80
points.
Although we did not detect PCR carryover in these
evaluations, we consider that this issue deserves careful
attention and intervention. To further improve the ability
to detect PCR carryover or sample mislabelling on a daily
basis, a software tool was created to evaluate similarities
between generated sequences in real time http://bioinf.
aids.gov.br/. With this tool, every generated sequence
was compared with the sequences previously generated
in a specific laboratory, and close similarities would raise
a flag and precipitate investigation and corrective mea-
sures, including retraining.
As noted in Table 2, the reported quality of sequences
according to the Phred quality scores was not high. For
the purpose of this evaluation, we intentionally set the bar
too high to encourage laboratories to pursue improve-
ments in the quality of sequences, as well as to increase
the number of redundant sequences available in the sys-
tem, as described in the Methods section.
Conclusions
In our network, we use licensed kits to generate our
results in our certified laboratories. As mentioned pre-
viously, the ViroSeq® v.2.6 was used from 2001 to 2007,
and the kit currently used is the TRUGENE® HIV-1 Gen-
otyping Assay. No changes in the performance of labora-
tories were detected during or after this transition,
according to our evaluation. Another large international
genotyping proficiency programme also demonstrated
that different technologies using ViroSeq, TruGene or in-
house assays successfully genotyped panel samples,
although variations in the quality of results have been
observed between laboratories [7].
Furthermore, we believe that our results emphasize
the importance of investing in employee training and in
increasing interpretation skills, especially in developing
countries that are using public (or scarce) resources to
manage the AIDS epidemic.
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